An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Inclusion Criteria: 1. Able and willing to provide a written informed consent 2. 18\~75 years old,male or female； 3. ECOG performance status 0 or 1 4. Unresectable locally advanced or metastatic gastrointestinal neuroendocrine tumors ( GEP-NETs ) of low and medium grade ( G1 or G2 ) confirmed by histopathology ; Exclusion Criteria: 1. Central nervous system metastasis is known. Patients who have previously received treatment ( radiotherapy or surgery ) for brain metastases and have no clinical symptoms can be enrolled if the pre-randomized pre-imaging is confirmed to be stable for at least 24 weeks. 2. There are clinical symptoms or diseases of the heart that are not well controlled. 3. Diabetes ( fasting blood glucose \> 2 × ULN ) that cannot be well controlled after optimal medical support treatment. 4. Severe urinary incontinence, hydronephrosis, severe micturition dysfunction or indwelling catheter for any reason